Search

Your search keyword '"Yavin, Yshai"' showing total 33 results
Start Over Author "Yavin, Yshai"
33 results on '"Yavin, Yshai"'

7. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Author

Mahaffey, Kenneth W., Jardine, Meg J., Bompoint, Severine, Cannon, Christopher P., Neal, Bruce, Heerspink, Hiddo J.L., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Capuano, George, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Sun, Tao, Wheeler, David C., Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Brenner, Barry M., and Perkovic, Vlado

Published
2019
Full Text
View/download PDF

12. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 PREDICTS CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: THE CREDENCE TRIAL

Author

Januzzi, James L., primary, Butler, Javed, additional, Sattar, Naveed, additional, Tefera, Eshetu, additional, Rosenthal, Norman, additional, Yavin, Yshai, additional, Bull, Scott, additional, Jardine, Meg, additional, Pollock, Carol, additional, Heerspink, Hiddo J.L., additional, and Hansen, Michael K., additional

Published
2022
Full Text
View/download PDF

13. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial

Author

Heerspink, Hiddo J.L., primary, Oshima, Megumi, additional, Zhang, Hong, additional, Li, Jingwei, additional, Agarwal, Rajiv, additional, Capuano, George, additional, Charytan, David M., additional, Craig, Jagriti, additional, de Zeeuw, Dick, additional, Di Tanna, Gian Luca, additional, Levin, Adeera, additional, Neal, Bruce, additional, Perkovic, Vlado, additional, Wheeler, David C., additional, Yavin, Yshai, additional, and Jardine, Meg J., additional

Published
2022
Full Text
View/download PDF

14. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Author

Sarraju, Ashish, primary, Li, JingWei, additional, Cannon, Christopher P., additional, Chang, Tara I., additional, Agarwal, Rajiv, additional, Bakris, George, additional, Charytan, David M., additional, de Zeeuw, Dick, additional, Greene, Tom, additional, Heerspink, Hiddo J.L., additional, Levin, Adeera, additional, Neal, Bruce, additional, Pollock, Carol, additional, Wheeler, David C., additional, Yavin, Yshai, additional, Zhang, Hong, additional, Zinman, Bernard, additional, Perkovic, Vlado, additional, Jardine, Meg, additional, and Mahaffey, Kenneth W., additional

Published
2021
Full Text
View/download PDF

17. Sodium‐glucose co‐transporter‐2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta‐analysis

Author

Li, Chao, primary, Zhou, Zien, additional, Neuen, Brendon L., additional, Yu, Jie, additional, Huang, Yuli, additional, Young, Tamara, additional, Li, Jingwei, additional, Li, Lin, additional, Perkovic, Vlado, additional, Jardine, Meg J., additional, Keay, Lisa, additional, Markoulli, Maria, additional, Rosenthal, Norm, additional, Capuano, George, additional, Yavin, Yshai, additional, Neal, Bruce, additional, and Arnott, Clare, additional

Published
2020
Full Text
View/download PDF

20. 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

Author

LI, JINGWEI, primary, NEAL, BRUCE, additional, HEERSPINK, HIDDO L., additional, ARNOTT, CLARE, additional, CANNON, CHRISTOPHER, additional, AGARWAL, RAJIV, additional, BAKRIS, GEORGE, additional, CHARYTAN, DAVID M., additional, ZEEUW, DICK DE, additional, GREENE, TOM, additional, LEVIN, ADEERA, additional, OH, RICHARD, additional, POLLOCK, CAROL A., additional, WHEELER, DAVID C., additional, YAVIN, YSHAI, additional, ZHANG, HONG, additional, ZINMAN, BERNARD, additional, DI TANNA, GIAN LUCA, additional, PERKOVIC, VLADO, additional, MAHAFFEY, KENNETH W., additional, and JARDINE, MEG, additional

Published
2020
Full Text
View/download PDF

21. CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS

Author

Sarraju, Ashish, primary, Li, JingWei, additional, Cannon, Christopher P., additional, Chang, Tara I., additional, Agarwal, Rajiv, additional, Bakris, George L., additional, Charytan, David M., additional, de Zeeuw, Dick, additional, Greene, Tom, additional, Heerspink, Hiddo J.L., additional, Levin, Adeera, additional, Neal, Bruce, additional, Pollock, Carol, additional, Wheeler, David C., additional, Yavin, Yshai, additional, Zhang, Hong, additional, Zinman, Bernard, additional, Perkovic, Vlado, additional, Jardine, Meg, additional, and Mahaffey, Kenneth W., additional

Published
2020
Full Text
View/download PDF

24. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Author

Perkovic, Vlado, Jardine, Meg J., Neal, Bruce, Bompoint, Severine, Heerspink, Hiddo J.l., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Cannon, Christopher P., Capuano, George, Chu, Pei-ling, De Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Wheeler, David C., Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Meininger, Gary, Brenner, Barry M., Mahaffey, Kenneth W., Bellary, Srikanth, Perkovic, Vlado, Jardine, Meg J., Neal, Bruce, Bompoint, Severine, Heerspink, Hiddo J.l., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Cannon, Christopher P., Capuano, George, Chu, Pei-ling, De Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Wheeler, David C., Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Meininger, Gary, Brenner, Barry M., Mahaffey, Kenneth W., and Bellary, Srikanth

Abstract

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m 2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular d

Published
2019

25. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Author

Perkovic, Vlado, primary, Jardine, Meg J., additional, Neal, Bruce, additional, Bompoint, Severine, additional, Heerspink, Hiddo J.L., additional, Charytan, David M., additional, Edwards, Robert, additional, Agarwal, Rajiv, additional, Bakris, George, additional, Bull, Scott, additional, Cannon, Christopher P., additional, Capuano, George, additional, Chu, Pei-Ling, additional, de Zeeuw, Dick, additional, Greene, Tom, additional, Levin, Adeera, additional, Pollock, Carol, additional, Wheeler, David C., additional, Yavin, Yshai, additional, Zhang, Hong, additional, Zinman, Bernard, additional, Meininger, Gary, additional, Brenner, Barry M., additional, and Mahaffey, Kenneth W., additional

Published
2019
Full Text
View/download PDF

26. Sodium‐glucose co‐transporter‐2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta‐analysis.

Author

Li, Chao, Zhou, Zien, Neuen, Brendon L., Yu, Jie, Huang, Yuli, Young, Tamara, Li, Jingwei, Li, Lin, Perkovic, Vlado, Jardine, Meg J., Keay, Lisa, Markoulli, Maria, Rosenthal, Norm, Capuano, George, Yavin, Yshai, Neal, Bruce, and Arnott, Clare

Subjects
TYPE 2 diabetes, META-analysis, GLYCOSYLATED hemoglobin, DIABETES, THERAPEUTIC complications
Abstract

Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors are effective for the treatment of macrovascular complications and nephropathy in type 2 diabetes, but effects on microvascular eye outcomes are unclear. We conducted a systematic review and meta‐analysis of randomized placebo‐controlled trials to evaluate the effect of SGLT2 inhibition on total ocular events and retinopathy in patients with type 2 diabetes. We searched MEDLINE and Embase for the period from database inception date to October 11, 2019. Two reviewers working independently extracted relevant data. Random‐effects models with inverse variance weighting were selected to estimate summary risk ratios (RRs) and 95% confidence intervals (CIs). We included nine studies, involving 39 982 patients with a mean follow‐up of 2.8 years. There were 1414 total ocular events, of which 624 were retinopathy events. SGLT2 inhibition was not associated with a change in the risk of total ocular events (RR 0.97, 95% CI 0.85, 1.11) or retinopathy (RR 0.98, 95% CI 0.84, 1.16), with consistent effects across studies (P for heterogeneity = 0.35 and 0.45, respectively). The effects of SGLT2 inhibition on eye disease in individuals with type 2 diabetes are probably null, although the available data cannot exclude small to moderate benefits or harms. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial

Author

Heerspink, Hiddo J.L., Oshima, Megumi, Zhang, Hong, Li, Jingwei, Agarwal, Rajiv, Capuano, George, Charytan, David M., Craig, Jagriti, de Zeeuw, Dick, Di Tanna, Gian Luca, Levin, Adeera, Neal, Bruce, Perkovic, Vlado, Wheeler, David C., Yavin, Yshai, and Jardine, Meg J.

Abstract

Canagliflozin reduced the risk of kidney failure and related outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in the CREDENCE trial. This analysis of CREDENCE trial data examines the effect of canagliflozin on the incidence of kidney-related adverse events (AEs).

Published
2021
Full Text
View/download PDF

33. Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

Author

Li, Jingwei, Neal, Bruce, Heerspink, Hiddo L., Arnott, Clare, Cannon, Christopher, Agarwal, Rajiv, Bakris, George, Charytan, David M., de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Oh, Richard, Pollock, Carol A., Wheeler, David C., Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Di Tanna, Gian Luca, Perkovic, Vlado, Mahaffey, Kenneth W., Jardine, Meg, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), and Groningen Kidney Center (GKC)

Catalog

Books, media, physical & digital resources
See catalog results